Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Two Things
View:
Post by lonc17 on May 15, 2024 12:24pm

Two Things

1. December date for OS breast cancer results? Wow, just in time!  That's darn close to the month that ONC will run out of cash and sprial into insolvency. MC will need outstanding BC OS results to keep his gravy train running. 

2. With the GCAR announcement we can all at last agree that ONC will NOT be running any phase 3 trials in any indication this year. Contrary to their stated goals and assurances in the past, ONC is NOT a phase 3 ready company. MC is a master at deception. Buyer beware.
Comment by Azzak34 on May 15, 2024 12:28pm
Haha what a transparent fool!! How flat is the earth Ionc17? 
Comment by Noteable on May 15, 2024 12:30pm
Two things ... (1) Accelerated Approval in pancreatic cancer & anal cancer and (2) Big Pharma acquisition to drive the process.
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities